H.C. Wainwright Reiterates Buy Rating on Prime Medicine (PRME)

October 2, 2024 6:44 AM UTC Send to a Friend
H.C. Wainwright analyst Arthur He reiterated a Buy rating and $10.00 price target on Prime Medicine (NASDAQ: PRME).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login